Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder

Nathan S. Teuscher, Aakwete Adjei, Robert L Findling, Laurence L. Greenhill, Robert J. Kupper, Sharon Wigal

Research output: Contribution to journalArticle

Abstract

A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactiv­ity disorder (ADHD). Using available data in healthy adults, a two-input, one-compartment, first-order elimination population pharmacokinetic model was developed using nonlinear mixed-effect modeling. The model was then extended to pediatric subjects, and was found to adequately describe plasma concentration–time data for this population. A pharmacokinetic/pharmacodynamic model was also developed using change from baseline in the ADHD Rat­ing Scale (ADHD-RS)-IV total scores from a pediatric Phase III trial and simulated plasma concentration–time data. During simulations for each MPH-MLR dose level (10–80 mg), increased body weight resulted in decreased maximum concentration. Additionally, as maximum concentration increased, ADHD-RS-IV total score improved (decreased). Knowledge of the relationship between dose, body weight, and clinical response following the administration of MPH-MLR in children and adolescents may be useful for clinicians selecting initial dosing of MPH-MLR. Additional study is needed to confirm these results.

Original languageEnglish (US)
Pages (from-to)2767-2775
Number of pages9
JournalDrug Design, Development and Therapy
Volume9
DOIs
StatePublished - May 26 2015

Fingerprint

Methylphenidate
Attention Deficit Disorder with Hyperactivity
Pharmacokinetics
Pediatrics
Population
Body Weight
Safety
5,10-dihydro-5-methylphenazine

Keywords

  • Aptensio XR™
  • Methylphenidate
  • MPH-MLR
  • Population pharmacokinetics

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Pharmacology
  • Drug Discovery

Cite this

Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder. / Teuscher, Nathan S.; Adjei, Aakwete; Findling, Robert L; Greenhill, Laurence L.; Kupper, Robert J.; Wigal, Sharon.

In: Drug Design, Development and Therapy, Vol. 9, 26.05.2015, p. 2767-2775.

Research output: Contribution to journalArticle

@article{5aac0437e53642778104989a7bea3de9,
title = "Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder",
abstract = "A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactiv­ity disorder (ADHD). Using available data in healthy adults, a two-input, one-compartment, first-order elimination population pharmacokinetic model was developed using nonlinear mixed-effect modeling. The model was then extended to pediatric subjects, and was found to adequately describe plasma concentration–time data for this population. A pharmacokinetic/pharmacodynamic model was also developed using change from baseline in the ADHD Rat­ing Scale (ADHD-RS)-IV total scores from a pediatric Phase III trial and simulated plasma concentration–time data. During simulations for each MPH-MLR dose level (10–80 mg), increased body weight resulted in decreased maximum concentration. Additionally, as maximum concentration increased, ADHD-RS-IV total score improved (decreased). Knowledge of the relationship between dose, body weight, and clinical response following the administration of MPH-MLR in children and adolescents may be useful for clinicians selecting initial dosing of MPH-MLR. Additional study is needed to confirm these results.",
keywords = "Aptensio XR™, Methylphenidate, MPH-MLR, Population pharmacokinetics",
author = "Teuscher, {Nathan S.} and Aakwete Adjei and Findling, {Robert L} and Greenhill, {Laurence L.} and Kupper, {Robert J.} and Sharon Wigal",
year = "2015",
month = "5",
day = "26",
doi = "10.2147/DDDT.S83234",
language = "English (US)",
volume = "9",
pages = "2767--2775",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Population pharmacokinetics of methylphenidate hydrochloride extended-release multiple-layer beads in pediatric subjects with attention deficit hyperactivity disorder

AU - Teuscher, Nathan S.

AU - Adjei, Aakwete

AU - Findling, Robert L

AU - Greenhill, Laurence L.

AU - Kupper, Robert J.

AU - Wigal, Sharon

PY - 2015/5/26

Y1 - 2015/5/26

N2 - A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactiv­ity disorder (ADHD). Using available data in healthy adults, a two-input, one-compartment, first-order elimination population pharmacokinetic model was developed using nonlinear mixed-effect modeling. The model was then extended to pediatric subjects, and was found to adequately describe plasma concentration–time data for this population. A pharmacokinetic/pharmacodynamic model was also developed using change from baseline in the ADHD Rat­ing Scale (ADHD-RS)-IV total scores from a pediatric Phase III trial and simulated plasma concentration–time data. During simulations for each MPH-MLR dose level (10–80 mg), increased body weight resulted in decreased maximum concentration. Additionally, as maximum concentration increased, ADHD-RS-IV total score improved (decreased). Knowledge of the relationship between dose, body weight, and clinical response following the administration of MPH-MLR in children and adolescents may be useful for clinicians selecting initial dosing of MPH-MLR. Additional study is needed to confirm these results.

AB - A new multilayer-bead formulation of extended-release methylphenidate hydrochloride (MPH-MLR) has been evaluated in pharmacokinetic studies in healthy adults and in Phase III efficacy/safety studies in children and adolescents with attention deficit hyperactiv­ity disorder (ADHD). Using available data in healthy adults, a two-input, one-compartment, first-order elimination population pharmacokinetic model was developed using nonlinear mixed-effect modeling. The model was then extended to pediatric subjects, and was found to adequately describe plasma concentration–time data for this population. A pharmacokinetic/pharmacodynamic model was also developed using change from baseline in the ADHD Rat­ing Scale (ADHD-RS)-IV total scores from a pediatric Phase III trial and simulated plasma concentration–time data. During simulations for each MPH-MLR dose level (10–80 mg), increased body weight resulted in decreased maximum concentration. Additionally, as maximum concentration increased, ADHD-RS-IV total score improved (decreased). Knowledge of the relationship between dose, body weight, and clinical response following the administration of MPH-MLR in children and adolescents may be useful for clinicians selecting initial dosing of MPH-MLR. Additional study is needed to confirm these results.

KW - Aptensio XR™

KW - Methylphenidate

KW - MPH-MLR

KW - Population pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84930643513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930643513&partnerID=8YFLogxK

U2 - 10.2147/DDDT.S83234

DO - 10.2147/DDDT.S83234

M3 - Article

C2 - 26060393

AN - SCOPUS:84930643513

VL - 9

SP - 2767

EP - 2775

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -